DC 102, a new glycosidic pyrrolo(1,4)benzodiazepine antibiotic produced by Streptomyces sp.

The Journal of Antibiotics
1988.0

Abstract

We have screened microorganisms isolated from soil and plants for their ability to produce antitumor antibiotics and isolated a new glycosidic pyrrolo(1,4)benzodiazepine antibiotic named DC102 from a cultured broth of a Streptomycete. In this communication, we report the production, isolation and characterization of DC 102. DC102 is a basic compound obtained as white powder. It showed the following properties: MP 120°C (dec); readily soluble in MeOH, EtOH, slightly soluble in H2O and Me2CO but insoluble in CHC13, n-hexane; UV λmax nm (ε) 210 (14,000), 244 (sh, 11,000), 310 (6,500); electron impact (EI)-mass m/z 429.2261 (M+ - CH3OH) (calcd for C23H31N3O5: 429.2242). The IR spectrum of DC 102 is shown in Fig. 1. The 13C NMR spectrum is given in Fig. 2. DC102 had a UV spectrum characteristic of pyrrolo(1,4)benzodiazepine antibiotics. It gave a positive reaction to β-anisidine, indicating the presence of a sugar moiety. However, its molecular formula is different from that of sibiromycin, the only aminoglycosidic pyrrolo(1,4)benzodiazepine antibiotic so far reported. DC102 exhibited weak antimicrobial activity against Gram-positive bacteria (Table 1). DC 102 was effective against murine leukemia P388, showing significant increase of life span (ILS 54%) at a dose of 0.5 mg/kg (Table 2). The LD50 value of DC 102 was 1.5 mg/kg (ip) in mouse. The detailed studies of the antitumor activity of DC 102 are in progress and will be published in due course.

Knowledge Graph

Similar Paper